INDIANAPOLIS — Verséa Ophthalmics recently has introduced several new technologies for eye care, including the Biovance 3L Ocular amniotic membrane allograft and the T-POC quantitative testing platform for ocular surface disease.
“We’ve been working really hard to build a team of dedicated folks to the eye care space, and we’ve also brought in a couple of novel technologies,” Rahim Hirji, RPh, vice president of marketing and clinical training and implementation at Verséa Ophthalmics, said in this Healio video.
According to Hirji, Biovance 3L Ocular is a fully